Drug Therapy in Stroke: From Preclinical to Clinical Studies

Harjeet Kaur  Ajay Prakash  Bikash Medhi
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Introduction

Stroke is one of the most devastating neurological conditions. It is the 3rd most common cause of death after coronary heart disease and cancer in developed countries. It is the 2nd most common cause of death above the age of 60 years, and the 5th most common cause in people aged 15–59 years [1]. Stroke or cerebral ischemia or a cerebral vascular accident is the sudden death of brain cells due to inadequate blood flow [2]. The risk for ischemic stroke is very high in cigarette smokers and diabetic patients at all ages, but this risk is most prominent in case of diabetes before 55 years of age in Black people and before 65 years of age in White people [3]. Stroke also increases the disability-adjusted life years (DALY) and makes the life of patients miserable. The burden of DALY was around 38 million in 1990 and will have increased to 61 million in 2020 worldwide due to stroke. It has been predicted that stroke will have moved from the 6th most common cause of DALY lost to the 4th in 2020 [4]. Despite widely available treatment options, still prevalence rates of stroke are high due to lower efficacy of drugs in clinical studies.

Pathophysiology

Cerebral ischemia may be defined as a condition of reduction in blood supply to the brain which leads to decreased availability of glucose and oxygen to brain cells.
As energy is essential to maintain ionic gradient brain homeostasis, the shortage of energy interrupts the energy-dependent processes in the brain. Stroke is mainly of two types: (1) ischemic stroke, caused when blood vessels supplying the brain are blocked by clot formation (50–85% of all strokes worldwide are ischemic), and (2) hemorrhagic stroke, caused when blood vessels become weak and their rupture leads to leakage of blood (13–15% of all strokes worldwide). The pathophysiology of stroke is complex and involves numerous processes including energy failure, loss of ion homeostasis, overload of intracellular calcium ion (Ca$^{2+}$) concentrations, excitotoxicity, activation of free radicals, release of cytokines, disruption to the blood-brain barrier (BBB), activation of glial cells and inflammation; these series of cascading events are well interrelated and coordinated, and they ultimately lead to necrosis and apoptosis. These events are not strictly in order but show overlaps. The extent of damage usually depends on the duration, severity and site of ischemia. Neurons require a constant supply of glucose and oxygen to conduct impulse transmission in order to maintain the ionic gradients across the membrane [5] (fig. 1).

The brain uses a lot of energy to synthesize ATP by oxidative phosphorylation and to regulate and maintain ionic gradient homeostasis. When the blood flow is interrupted, inhibition of mitochondrial ATP synthesis occurs, which permits the influx of Na$^+$ and the efflux of K$^+$ ions from the cell [6]. Hence, this disturbs the whole homeostasis and leads to cell membrane depolarization. The elevated intracellular levels of Ca$^{2+}$, Na$^+$ and ADP cause mitochondria to release a deleterious amount of reactive oxygen species, which causes oxidative damage. Various cytokines act on astrocytes and microglia and activate the formation of matrix metalloproteinases. Once stimulated, it causes disruption of the BBB, leading to vasogenic edema and hemorrhage, damaging capillaries, collagen and laminins in the basal lamina, which further degrades the composition of the vascular wall and enhances BBB permeability, causing neuronal death by necrosis as well as apoptosis [7] (fig. 2).

**Fig. 1.** Main targets of stroke.
greatly increased our understanding of the fundamental biology of ischemic brain injury and have laid a strong foundation for future development [9].

**Drug Development Status**

A recent view has been that ‘everything works in animals but nothing works in humans’, as successes of clinical trials declined over the successes of preclinical studies. Neuroprotective drugs for stroke were first initiated during the 1980s and are still in development. The basic aim of neuroprotection is to interfere with the events of the ischemic cascade, to halt the pathological processes and to prevent the death of vulnerable nerve cells in the ischemic penumbra. Despite the positive results from experimental animal studies, almost all clinical trials of neuroprotective therapies to date have not shown any success [10, 11].

**Clinical Trials Failed: Why?**

The sweet success of neuroprotective agents in animal studies and the bitter aftertaste in clinical studies of stroke have recently been a major topic of discussion in research. Reasons for such a fundamental failure may be [12]:

1. **Time window**: preclinical studies have used very short time windows for drug administration, whereas longer time windows are permitted in clinical trials.
2. **Target**: preclinical studies target the ischemic penumbra, whereas clinical trials do not.
3. **Duration**: the optimal duration of neuroprotectant administration is unknown.
4. **Outcome**: preclinical studies use different outcome measures such as infarct size to judge therapeutic efficacy, whereas clinical trials use clinical and functional end points measured by the modified Rankin Scale and the Barthel index.
5. **Preclinical studies have relied on early outcomes, whereas clinical trials rely on late assessments**.
6. **Diversity of stroke types**: most of the preclinical studies use middle cerebral artery occlusion as a model of ischemic stroke and therefore do not mimic the pathophysiological heterogeneity of different stroke types, as well as their extent, duration of ischemia and severity; by contrast, human studies include patients with a broad pathophysiological heterogeneity.
7. **Differences in comorbidities**: most of the experimental models use young healthy rodents which are not exposed to other medications, whereas stroke patients often suffer from several severe comorbidities (prior ischemic attack, cardiovascular diseases, etc.) and have premedication with other drugs.

---

**Fig. 2.** Basic cascade of stroke. ROS = Reactive oxygen species; TNF-α = tumor necrosis factor-α; IL-β = interleukin-β; MMP = matrix metalloproteinase; ER = endoplasmic reticulum.
Preclinical and Clinical Studies

In preclinical studies, over a thousand of potential neuroprotective therapies have been used to target some of the molecular events, with many of these shown to be protective. To date, various cascades of events which lead to the pathophysiology of stroke have been targeted to reduce its deteriorating effect [13]. Different therapeutic approaches tried on animals as well as in clinical trials are discussed below and summarized in table 1.

Antithrombotic Agents

Preclinical Output

Heparin. Heparin is widely used for the treatment of acute stroke. Intravenous heparin sodium could be very effective in the earliest treatment of acute nonlacunar hemispheric cerebral infarction, but at the same time it also increases the incidence of intracranial symptomatic brain hemorrhages [13]. An in vitro study of ultra-low-molecular-weight heparin which was carried out on cultured PC12 cells exposed to Earle’s solution containing sodium dithionite showed significant inhibition of cell damage induced by oxygen glucose deprivation. Heparin also exerted neuroprotective effects by significantly reducing the infarct volume in rats with focal cerebral ischemic injury at doses of 0.5 and 1.0 mg/kg [14] and partly by improving energy metabolism, inhibiting apoptosis and attenuating the inflammatory reaction [15].

Enoxaparin. Intravenous administration of enoxaparin significantly reduces infarct size, improves the neuroscore in both permanent and transient focal ischemia in rats, exhibits a large therapeutic window of at least 5 h and is devoid of major hemorrhagic risk [16].

Clinical Output

Heparin. In an observational study, ultra-slow continuous intravenous infusion of unfractionated heparin can has significantly reduced the neurological deficit score of patients with progressive cerebral infarction [17].

Enoxaparin. In a phase IV study of enoxaparin, long-term neurological outcome improved and the frequency of symptomatic intracranial hemorrhages decreased in patients for venous thromboembolism prophylaxis (blood clot forming within a vein) [18].

Antiplatelet Agents

Preclinical Output

Cilostazol. Recent animal studies showed a neuroprotective role of cilostazol in transient focal cerebral ischemia against ischemic brain injury and hemorrhagic transformation [19].

Eptifibatide. Preclinical data from an embolic mouse model demonstrated that the combination of a fibrinolytic agent with eptifibatide, a glycoprotein (GP)IIb/IIIa inhibitor, increased the efficiency in dissolving an embolus, decreased the infarct volume, and improved microvascular patency compared with a fibrinolytic agent alone. Treatment with rt-PA and a GPIIb/IIIa antagonist reduced perfusion deficits and significantly enhanced cortical perfusion [20].

Abciximab. In preclinical studies, abciximab was found to be protective against ischemic stroke [10].

Clinical Output

Aspirin and Cilostazol. In a randomized, double-blind noninferiority trial, cilostazol was found to be more feasible, efficacious and safe than aspirin in acute ischemic stroke [21] and could be an effective neuroprotective agent in patients with noncardioembolic stroke [22]. In a multicenter, randomized, double-blind, placebo-controlled trial, patients were randomly assigned to receive either placebo or 100 mg cilostazol twice a day as well as 100 mg aspirin a day. Cilostazol decreased the transcranial Doppler pulsatility index at 90 days from baseline compared with placebo in acute lacunar infarction (lacunar infarcts are a frequent type of stroke caused mainly by cerebral small-vessel disease). This result may be related to pleiotropic effects such as vasodilation, beyond its antiplatelet activity [23]. A phase III study of cilostazol-aspirin in recurrent stroke with intracranial artery stenosis was completed and its results are still awaited [24].

Eptifibatide. Intravenous eptifibatide is an FDA-approved drug for the treatment of blood clots causing heart attack and chest pain. Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen. The CLEAR (Study of the Combination Therapy of rt-PA and Eptifibatide to Treat Acute Ischemic Stroke) showed the safety of the use of a combination of low-dose rt-PA and a GPIIb/IIIa antagonist (eptifibatide) in acute ischemic stroke patients who were treated within 3 h after symptom onset. The safety profile of the combination regimen was excellent when using 0.6 mg/kg rt-PA plus eptifibatide versus standard-dosed rt-PA. The efficacy of this trial has led to a phase III clinical trial [25]. The CLEAR-ER, a phase II trial, begun in July 2009 to determine whether intravenous treatment with a medium dose of rt-PA plus eptifibatide started within 3 h after symptom onset might have a better outcome than standard (intravenous) treatment with rt-PA alone. Data on
the primary outcome measure were collected in October 2012 and the results are still awaited [26].

**Abciximab.** A phase III trial was terminated prematurely after having enrolled 808 patients in all cohorts, at the recommendation of an independent safety and efficacy monitoring board due to an unfavorable benefit-risk profile, as there were increased rates of symptomatic and fatal intracranial hemorrhage in the primary and wakeup cohorts [27].

**Aspirin and Clopidogrel.** The risk of recurrent stroke and the risk of major hemorrhage was high with dual antiplatelet therapy as compared with aspirin alone. Even dual therapy did not reduce the mortality rate (77 deaths in the group receiving aspirin alone vs. 113 in the group receiving dual antiplatelet therapy) [28]. A phase IV study aiming to compare the preventive effect of triflusal and clopidogrel in ischemic stroke patients based on the cytochrome P450 2C19 polymorphism was started in March 2010. About 795 patients have been enrolled so far and the study is estimated to be completed in January 2015 [29].

**Thrombolytic Agents**

**Preclinical Output**

**t-PA and Streptokinase.** Various experimental studies have shown the neuroprotective potential of t-PA and streptokinase [10].

**Clinical Output**

**t-PA.** Intravenous injection of rt-PA is the only treatment that has been approved for acute ischemic stroke by the FDA (in 1996). This was based on the results of clinical research on rt-PA conducted by the National Institute of Neurological Disorders and Stroke in 1995, and rt-PA is the only drug approved by the FDA that has to be injected within 3 h after onset [30], in spite of an increased risk of symptomatic intracerebral hemorrhage [31].

**t-PA and Urokinase.** Treatment with conventional-dose intravenous rt-PA and its combination with intracerebral urokinase were safe and feasible in patients. This strategy achieved high rates of complete arterial recanalization and good functional outcomes [32]. The administration of urokinase within 24 h after onset of stroke significantly improved the clinical outcomes as compared with a control group, which agreed with results from previous reports on the action of thrombolytic agents. Urokinase also showed a significant effect (in terms of the increase in cerebral blood flow to ischemic brain tissues and prevention of the spread of cerebral thrombi) if administered to patients even more than 24 h after the onset of strokes. Only 2 out of 93 patients in the urokinase treatment group showed minor hemorrhagic transformation. This value is noticeably lower than that shown in previous studies. However, mild hemorrhage in the gastrointestinal tract and hemorrhage in the oral cavity that could be readily controlled by drugs were shown in 8 of the 93 patients [33].

**Calcium Channel Blockers**

**Preclinical Output**

**Nimodipine.** The results of a systematic review of experimental studies did not show convincing evidence to begin trials with nimodipine on a large number of patients. The review included 20 studies out of 225 identified articles. The methodological quality of the studies was poor. Among the included studies, 50% (10 studies) were in favor of nimodipine and showed statistically significant effects [34].

**Clinical Output**

**Nimodipine.** In a Cochrane review, the authors reported around 19 studies which assessed the effects of a calcium antagonist (nimodipine) in patients with ischemic stroke. No difference in death rates or survival free of disability was observed between patients who received nimodipine and those who did not. There was no evidence that giving nimodipine (calcium antagonists) after acute ischemic stroke could save lives or reduce disability [35].

**Antioxidants**

**Preclinical Output**

**NXY-059.** NXY-059 was found to be neuroprotective in animal models by reducing infarct size [36, 37].

**Ebselen.** Ebselen showed an antioxidant effect by repressing lipid peroxidation and inhibiting inducible nitric oxide synthase protein expression in cerebral cortex homogenate in stroke-prone, spontaneously hypertensive rats [38].

**Tirilazad.** A systematic review of studies on tirilazad demonstrated its efficacy in animal models of focal ischemia by reducing the infarct volume by 29.2% and improving the neurobehavioral score by 48.1% [39].

**Edaravone.** Edaravone significantly reduced the infarct volume and improved the neurological deficit scores at 24 h after reperfusion in transient focal ischemia in mice [40]. Edaravone significantly reduced oxidative cell death in both HT22 neuronal cells and primary rat astrocytes [41].
Clinical Output

NXY-059. In a randomized, double-blind, placebo-controlled trial involving 1,722 patients, administration of NXY-059 within 6 h after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the National Institutes of Health Stroke Scale score [42]. In a phase III trial, NXY-059 was shown to be ineffective in the treatment of acute ischemic stroke within 6 h after the onset of symptoms [43].

Ebselen. A phase III trial of 394 patients was started in 2001; either 150 mg ebselen or placebo was administered to patients twice per day within 24 h after stroke, and the patients were treated continuously for 14 days. The results are not available yet [44].

Tirilazad. Tirilazad did not show a significant effect on infarct volume in patients with acute ischemic stroke [45].

Edaravone. Edaravone ameliorated the size of ischemic stroke lesions and neurologic deficits in patients with small-vessel occlusion, i.e. lacunar infarction, within 1 year, while there were no significant differences in outcome after 1 year [46]. In a study comparing edaravone and citicoline in acute ischemic stroke, edaravone was more effective with a better neurological outcome at 3 months than citicoline [47].

GABA Agonists

Preclinical Output

Clomethiazole. Clomethiazole was protective at plasma concentrations of 6.1 μmol/l and above and at 3.5 μmol/l and above, respectively. Therefore, clomethiazole was neuroprotective in both global and focal ischemia models at plasma concentrations known to be well tolerated by stroke patients [48]. Clomethiazole also provided significant neuroprotection with limited functional preservation in a model of global ischemia [49].

Clinical Output

Clomethiazole. In the CLASS-I (Clomethiazole Acute Stroke Study in Ischemic Stroke), a randomized, double-blind, binational (USA and Canada), multicenter, placebo-controlled study, a total of 1,198 patients with major ischemic stroke and a combination of limb weakness, higher cortical dysfunction and visual field deficits were randomly assigned to clomethiazole (68 mg/kg intravenously over 24 h) treatment or placebo. The results suggest that clomethiazole has no effect on disability, stroke deficit or infarct volume in patients with major ischemic stroke [50].

Competitive NMDA Antagonists

Preclinical Output

CGS 19755. CGS 19755 has shown to be effective in preclinical studies at a dose of 40 mg/kg by reducing infarct size by approximately 50% [51].

Clinical Output

CGS 19755. After safe and effective results of a phase II study, two pivotal phase III, double-blind, randomized, placebo-controlled, parallel-design ischemic stroke trials enrolled a total of 567 patients to which a single intravenous 1.5 mg/kg dose of CGS19755 was administered within 6 h after stroke onset. The trial was suspended on the advice of the independent Data Safety Monitoring Board (DSMB) because of high mortality rates of 22% in the CGS 19755 group and of 17% in the placebo-treated group. Thus, the high mortality rate particularly within the first 30 days, and in patients with severe stroke, suggests that the drug might have a neurotoxic effect. So, these trials were also terminated prematurely on the advice of the independent DSMB, based on an overall mortality imbalance [52, 53].

Noncompetitive NMDA Antagonists

Preclinical Output

Aptiganel (CNS-1102). Aptiganel was effective in a rat model of focal ischemia by providing a shield to cerebral gray matter as well as white matter from ischemic injury and by preventing the degeneration of myelin and axons [54].

MK-801. MK-801 only improved normothermic animals, whereas hypothalamic damage with hyperthermia masked the neuroprotective effect of MK-801 in focal cerebral ischemia [55]. MK-801-treated rats had shown significantly (p < 0.05) better neurological outcome and good recovery [56].

Clinical Output

Aptiganel. Aptiganel was not found to be efficacious in a phase II/III randomized controlled trial involving 628 patients with hemispheric ischemic stroke. The trial was suspended by the sponsor and the independent DSMB because of both a lack of efficacy and a potential imbalance in mortality [57].

AMPA Antagonists

Preclinical Output

ZK 200775. ZK 200775 (MPQX) significantly reduced infarct size in a transient middle cerebral artery occlusion model of ischemic stroke [58].
YM872. YM872 significantly decreased infarct volume, ameliorated the neurological deficit score in a rat embolic stroke model [59] and was neuroprotective by decreasing loss of cortical tissue and cerebral edema after traumatic brain injury [60].

Clinical Output

ZK 200775. The AMPA antagonist ZK 200775 transiently worsened the neurological condition of patients with acute ischemic stroke. The results showed significant adverse (neuronal dysfunction, glial cell toxicity, sedation) effects in patients with acute stroke [61].

YM872. A phase II trial started in 2000 in which 24-hour infusions of YM872 were given within 6 h after stroke onset. The diminution of ischemic lesion volume is measured by magnetic resonance imaging 28 days after the infusion has been given, and neurological function and disability scores are assessed at follow-up visits through day 90 of the study. Results have not been published yet [62] (table 1).

Phase III Trials

Neuroprotective drugs in the development pipeline are summarized below (table 2).

Hypothermia (Cooling Effect)

Hypothermia is one of the most promising neuroprotective strategies currently under clinical investigation. It consists of cooling down the brain temperature. Hypothermia has shown significant preclinical efficacy in animal models of cerebral ischemia [63] and has been shown to be feasible in acute stroke patients using either surface

<p>| Table 1. Summary of neuroprotective agents in preclinical and clinical studies |</p>
<table>
<thead>
<tr>
<th>No.</th>
<th>Compound</th>
<th>Preclinical output</th>
<th>Clinical output</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Antithrombotic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>Heparin</td>
<td>(i) effective [13–15]</td>
<td>(i) effective [17]</td>
</tr>
<tr>
<td>(ii)</td>
<td>Enoxaparin</td>
<td>(ii) effective [16]</td>
<td>(ii) phase IV: effective [18]</td>
</tr>
<tr>
<td>2</td>
<td>Antiplatelet agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>Clopidogrel</td>
<td>–</td>
<td>(i) phase IV: ongoing [29]</td>
</tr>
<tr>
<td>(iii)</td>
<td>Abciximab</td>
<td>(iii) effective [10]</td>
<td>(iii) phase III: terminated [27]</td>
</tr>
<tr>
<td>(iv)</td>
<td>Eptifibatide</td>
<td>(iv) effective [20]</td>
<td>(iv) phase II: results awaited [26]</td>
</tr>
<tr>
<td>3</td>
<td>Thrombolytic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>t-PA</td>
<td>(i) effective [10]</td>
<td>(i) phase III: effective [30, 31]</td>
</tr>
<tr>
<td>4</td>
<td>Calcium channel blockers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>Nimodipine</td>
<td>(i) effective [34]</td>
<td>(i) ineffective [35]</td>
</tr>
<tr>
<td>5</td>
<td>Antioxidants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>NXY-059</td>
<td>(i) effective [36, 37]</td>
<td>(i) phase III: ineffective [43]</td>
</tr>
<tr>
<td>(ii)</td>
<td>Tirilazad</td>
<td>(ii) effective [39]</td>
<td>(ii) ineffective [45]</td>
</tr>
<tr>
<td>(iii)</td>
<td>Edaravone</td>
<td>(iii) effective [40, 41]</td>
<td>(iii) effective [46, 47]</td>
</tr>
<tr>
<td>6</td>
<td>GABA agonist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>Clomethiazole</td>
<td>(i) effective [48, 49]</td>
<td>(i) ineffective [50]</td>
</tr>
<tr>
<td>7</td>
<td>Competitive NMDA antagonists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>CGS 19755</td>
<td>(i) effective [51]</td>
<td>(i) phase III: ineffective [53]</td>
</tr>
<tr>
<td>8</td>
<td>Noncompetitive NMDA antagonists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>Aptiganel</td>
<td>(i) effective [54]</td>
<td>(i) phase III: ineffective [57]</td>
</tr>
<tr>
<td>(ii)</td>
<td>MK-801</td>
<td>(ii) effective [55, 56]</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>AMPA antagonists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>ZK 200775</td>
<td>(i) effective [58]</td>
<td>(i) ineffective [61]</td>
</tr>
<tr>
<td>(ii)</td>
<td>YM872</td>
<td>(ii) effective [59, 60]</td>
<td>(ii) phase II: results not appeared yet [62]</td>
</tr>
</tbody>
</table>
cooling or endovascular cooling [64, 65]; it is currently being investigated in both safety and efficacy trials: the COAST-II (Cooling in Acute Stroke), the CHILI (Controlled Hypothermia in Large Infarction) and the Euro-HYP (European Stroke Research Network for Hypothermia)-1 trials [66, 67].

**Magnesium Sulfate**
Magnesium has demonstrated its neuroprotective effect in animal studies [68] as well as in a phase II study on stroke patients [69]. Magnesium had failed to show a significant effect on the primary end point or on any secondary end point in a previous phase III trial [70]. Currently, the FAST-MAG (Field Administration of Stroke Therapy – Magnesium) trial includes 1,700 stroke patients receiving a dose of 4 g (intravenously) over 15 min, followed by a maintenance infusion of 16 g over 24 h after arrival at the hospital; it was started in January 2005 and is still in progress [71].

**Uric Acid**
Uric acid showed its efficacy in animal studies [72] and was safe in a phase II trial [73]. The ongoing phase III trial URICO-ICTUS (Efficacy Study of Combined Treatment with Uric Acid and rt-PA in Acute Ischemic Stroke) was started in June 2011 to assess the clinical efficacy of uric acid administration in acute ischemic stroke patients treated with rt-PA within 4.5 h after stroke onset and is supposed to be completed in December 2013 [74].

**Dapsone**
Dapsone has been safe and beneficial in animal studies [75] and a clinical pilot study with 30 patients [76]. A phase III trial using a dose of 250 mg (intravenously) administered within 12 h after onset is still in progress [77].

**Cromolyn**
Cromolyn has been very effective in reducing brain edema and BBB permeability in animal models of stroke

<table>
<thead>
<tr>
<th>No.</th>
<th>Neuroprotective strategy</th>
<th>Molecular structure</th>
<th>Mechanism of action</th>
<th>Preclinical output</th>
<th>Clinical output</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hypothermia</td>
<td>cooling effect</td>
<td>reduce cerebral oxygen metabolism, synaptic inhibitor</td>
<td>effective [63]</td>
<td>COAST-II and CHILI trial [67, 68]</td>
</tr>
<tr>
<td>2</td>
<td>Magnesium sulfate (MgSO₄)</td>
<td>[Mg²⁺]</td>
<td>antiseizure, NMMA ion channel blocker</td>
<td>effective [69]</td>
<td>phase II: effective [70]; phase III (FAST-MAG trial): ongoing [71]</td>
</tr>
<tr>
<td>3</td>
<td>Uric acid (C₅H₄N₄O₃)</td>
<td>[O]</td>
<td>free radical scavenger</td>
<td>effective [72]</td>
<td>phase II: effective [73]; phase III (URICO-ICTUS): ongoing [74]</td>
</tr>
<tr>
<td>4</td>
<td>Dapsone (C₁₂H₁₂N₂O₂S)</td>
<td>[O]</td>
<td>anti-inflammatory, antioxidant</td>
<td>effective [75]</td>
<td>clinical pilot trial: effective; phase III: ongoing [77]</td>
</tr>
<tr>
<td>5</td>
<td>Cromolyn (C₂₃H₁₆O₁₁)</td>
<td>[O]</td>
<td>mastocyte stabilization, reduction in BBB leakage</td>
<td>effective [78, 79]</td>
<td>phase III: ongoing [80]</td>
</tr>
<tr>
<td>6</td>
<td>Ebselen (C₁₃H₉NOSe)</td>
<td>[O]</td>
<td>antioxidant</td>
<td>effective [38]</td>
<td>phase III: ongoing [44]</td>
</tr>
</tbody>
</table>
A phase III clinical trial of acute ischemic stroke is still going on [80].

Statins

Statins (rosuvastatin) significantly protected the brain from ischemic stroke in mice [81]. Another statin, simvastatin, is tested in a phase IV study, started in 2009, including 340 patients. Results are still awaited [82].

Cyclosporin A

Cyclosporin A was neuroprotective in a permanent middle cerebral artery occlusion and homolateral transient common carotid artery occlusion model of rodents [83]. Phase II is in progress [84] (table 2).

Discussion

Stroke or cerebral ischemia is not only affecting public health but also posing a big threat by the social and economic burden it imposes on society. The higher rates of incidence, mortality and DALY in low- and middle-income countries are a matter of concern. New neurotherapeutic agents are urgently required to reduce the incidence as well as to treat the aftermath of stroke. However, despite the encouraging results from preclinical studies, stroke continues to be a big question mark for both neuroscientists and clinicians. To date, thousands of neuroprotective agents have proved successful in experimental studies, but no new treatment has shown to be effective since t-PA was approved in 1996. The discrepancy between animal models and stroke occurring in humans tells a story of positive output of preclinical studies and of failure of clinical studies. Our past experience with stroke research increased our understanding of the epidemiology and pathophysiology of stroke, but we should focus on well-planned strategies: how to prevent injury due to reperfusion, and which is more beneficial – single drug administration or combined drug therapy for multiple targets in the brain. The novel approach should include increased blood restoration and increased survival rates of neurons in the penumbra region. Several agents are currently in clinical trials and they may fulfill the promises of neuroprotection. Before moving to clinical trials, drugs should be re-evaluated based on animal studies. Awareness programs should be implemented, especially in developing countries, so that people who are at great risk of stroke visit medical health institutes frequently. Translating bench success to the bedside has been discouraging. Despite the successful story of preclinical trials, there is still a need to establish animal models resembling the human disease, so that the translation of results from preclinical studies to clinical practice can be improved.

References


